EQL Pharma AB (publ) (STO:EQL)

Market Cap	1.91B -17.7%
Revenue (ttm)	425.75M +25.8%
Net Income	29.34M -15.5%
EPS	0.98 -15.6%
Shares Out	29.53M
PE Ratio	66.15
Forward PE	34.75
Dividend	n/a
Ex-Dividend Date	n/a

Volume	47,964
Average Volume	33,132
Open	62.00
Previous Close	61.60
Day's Range	60.30 - 65.60
52-Week Range	46.55 - 98.60
Beta	0.41
RSI	63.05
Earnings Date	Feb 3, 2026

About EQL Pharma AB

EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2006
• Employees: 55
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: EQL

Financial Performance

In fiscal year 2025, EQL Pharma AB's revenue was 373.52 million, an increase of 41.39% compared to the previous year's 264.17 million. Earnings were 43.12 million, an increase of 89.93%.